Introduction
The primary mechanism of imatinib resistance in chronic myeloid leukemia (CML) is point mutations in the BCR-ABL kinase domain that decrease inhibitor sensitivity. L248V is a mutation in the ATP-binding loop (P-loop) that has been shown to confer a high level of imatinib resistance. 1 It has recently been reported that L248V introduces a secondary 5 0 donor splice site into ABL exon 4.
2 Alternative splicing at this site results in the coexpression of a mutant with deletion of residues 248-274 (D248-274), which lacks part of the kinase domain's N-terminal lobe. The lack of critical structures including the P-loop led to the prediction that D248-274 is kinase inactive. Missplicing of BCR-ABL mRNA has also been observed in a significant portion of patients without the L248V mutation, indicating that coexpression of deletion mutants and native BCR-ABL may be common. 3, 4 BCR-ABL forms a dimer and/or tetramer through the coiledcoil domain in the N terminus of BCR, which is thought to promote BCR-ABL activation and oncogenesis by facilitating transphosphorylation. 5, 6 Given the requirement for dimerization for kinase activation, it is conceivable that the deletion mutants have a dominant-negative effect on the native BCR-ABL by formation of heterodimers with decreased transphosphorylation. Here, we report the frequency of deletion mutants in patients on imatinib therapy, and analyze their properties alone and when coexpressed with native BCR-ABL.
Materials and methods

Patient samples
This study was approved by the Institutional Review Board of Oregon Health and Science University and informed consent was obtained from all patients. Mononuclear cells were isolated from bone marrow aspirates or peripheral blood samples by density gradient centrifugation. Aliquots of cells were used for RNA extraction (RLT reagent, Qiagen, Valencia, CA, USA). qRT-PCR for BCR-ABL was performed on peripheral blood or bone marrow aspirate specimens as described. 7 
Mutation analysis
RNA was isolated with the RNeasy kit (Qiagen, Valencia, CA, USA). Superscript reverse transcriptase was used to synthesize cDNA with random hexamer primers (Invitrogen, Carlsbad, CA, USA). Nested PCR was performed from BCR to Abl exon 8 as described 8 with automated sequencing of the 1.5 kb BCR-ABL product. We have found this direct sequencing procedure to have sensitivity for mutant transcripts comprising of at least 30% of the PCR product. 9 To detect deletion mutants chromatograms were visually analyzed for regions with a sudden deterioration of sequence quality due to noise. We estimate that the detection limit for this has to be roughly equivalent to the detection limit for point mutations. In three patients PCR products were subcloned using the TOPO-TA cloning kit (Invitrogen) and a minimum of 16 individual colonies were sequenced. Mutations occurring in only one subclone were discarded.
Generation of mutant alleles
To generate expression constructs the AatII/KpnI ABL kinase domain fragments were cut from pCR4-TOPO containing deletion mutations and pasted into full-length BCR-ABL in pGEM5. The BCR-ABL variants were then cloned into MSCV-IRES-GFP (MIGR1) using the Gateway Vector cloning system (Invitrogen). To generate c-Abl expression constructs, deletion mutation were introduced by site-directed mutagenesis using the Quik-Change site directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and pSGT-c-Abl 1b as template. 10 All deletions were confirmed by sequencing.
Cell lines
The Ba/F3 cells were maintained as described.
11 TonB210 cells were kindly provided by George Daley (Children's Hospital, Boston, MA, USA). For the TonB210 cell experiments, BCR-ABL was induced by addition of 1 mg ml À1 doxycycline to the culture. Ba/F3 cells were transduced with viral supernatants from 293T cells transfected with wild-type and mutant BCR-ABL-MIGR1 constructs. Isolation of Bcr-Abl expressing cells was performed by cell sorting for GFP expression using a FACS Aria (BD Biosciences, San Diego, CA, USA).
Immunoblotting
BCR-ABL and c-ABL autophosphorylation were detected by immunoblot with mouse monoclonal anti-phosphotyrosine antibody 4G10 (Upstate Biotechnology, Waltham, MA, USA). BCR-ABL expression was detected with rabbit anti-ABL antibody K12 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Loading controls were performed by immunoblot with anti-actin (Ab-1) mouse monoclonal (JLA20) antibody (Calbiochem, San Diego, CA, USA).
Kinase assays
Transfection of HEK293 cells, immunoprecipitation of ABL protein and ABL in vitro kinase assay was carried out as described previously. 12, 13 The relative concentration of immunoprecipitated ABL protein was determined by immunoblotting (anti-ABL Ab-3, Oncogene Science, Cambridge, MA, USA) and subsequent quantification using the Li-cor Odyssey system and normalized for c-ABL wild-type.
Cell proliferation assays
Cell line dependence on IL-3 and sensitivity to imatinib were tested independently in MTS-based viability assays (CellTiter 96 Aqueous One Solution Reagent; Promega, Madison, WI, USA) as described. 14 The mean of two independent cell lines is reported for each condition as the percentage absorbance compared to the control concentration (1 ng ml À1 for IL-3, no imatinib).
Results
Characterization of abnormal BCR-ABL transcripts from CML patients
In sequencing of BCR-ABL for kinase domain mutations, we have occasionally observed smaller bands in addition to the expected PCR product on agarose gel electrophoresis and/or overlapping sequence on high-quality kinase domain sequence traces (data not shown). This prompted us to perform a systematic analysis with a retrospective screen of randomly selected patient samples. To analyze the entire PCR product in these patients, sequencing was done using primers covering the ABL Cap, SH3, SH2 and kinase domains. We screened 95 patients with a median age of 54 (range, 22-80) years, median disease duration of 49 months (range, 4-186) and median time on imatinib of 23 months (range, 2-52). Among these patients, 79 began therapy during chronic phase, 15 in accelerated phase and one in blast crisis. At mutation analysis, 36 had a complete cytogenetic response, 22 major cytogenetic response, 32 complete hematologic response and four hematologic relapse. In this group, 14 (15%) patients had a deletion mutation (Table 1) . Five patients were found to harbor D184-274, corresponding to a complete loss of ABL exon 4. One of these five also had the point mutation M244V. Three patients had an alternative transcript joining BCR sequence to ABL exon 4, resulting in out of frame (OOF) ABL translation (D27-183 OOF, stop at 296) as previously described. 4 Two patients were found to have D248-274, previously reported to coexist with the L248V mutant. 2 In another patient, loss of ABL exon 7 was detected, also resulting in a frame-shift (D362-444 OOF, stop at 458). The D342-383 mutant was detected in two patients, one of whom also had the Q333R point mutation. Lastly, the D151-183 mutant was detected in a single patient. Thus, deletion mutants detected in patients most frequently involved splice junctions.
We decided to concentrate our studies on the in-frame mutations that were most common in our patients, D248-274 and D184-274. To confirm the precise borders of these deleted sequences, we subcloned the PCR products and sequenced Estimates of deletion mutant sequence are limited by the sensitivity of direct sequencing and likely are within a range ± 20%.
BCR-ABL deletion mutants in CML patients DW Sherbenou et al multiple single clones from three of the patients. For each patient, two independent samples from different time points were tested (Table 2) . Of the three patients, two had the L248V/ D248-274 combination and one the D184-274 mutant. Subcloning of BCR-ABL amplicons confirmed the suspected deletion borders and revealed that both patients with the L248V and D248-274 mutants also expressed the D184-274 mutant. Both patients with the L248V mutant tested at different time points showed the continued presence of the D248-274 deletion.
BCR-ABL P-loop deletion mutants are catalytically inactive
Deletion of residues 248-274 eliminates two of the five strands of the b-sheet of the N-terminal lobe of the kinase domain and the glycine-rich loop (P-loop). Both regions provide essential residues for ATP-binding and catalysis of phosphoryl transfer ( Figure 1a) . 15 In the D184-274 mutant, the C-terminal a-helix (aB) of the SH2 domain and the linker between the SH2 and kinase domains are missing in addition to the two beta strands of the N-lobe and the P-loop (Figure 1b) . Given the important functional role of these motifs, we hypothesized that their deletion may result in the loss of enzymatic activity.
To test the effects of the deletions on ABL kinase function, we introduced the deletions into c-ABL and overexpressed the mutant proteins in HEK293 cells and assayed whole-cell extracts for protein tyrosine phosphorylation. Neither c-ABL D184-274 nor c-ABL D248-274 expressing cells showed detectable levels of cellular tyrosine phosphorylation, in contrast to a constitutively active form of c-ABL containing P223E/P230E double mutations (ABL PP) 10 ( Figure 2a ). Moreover, a slight increase in cellular tyrosine phosphorylation could be observed by overexpression of the wild type c-ABL protein, but overexpression of the deletion mutants showed no tyrosine phosphorylation. Immune complex in vitro kinase assays showed that the deletion mutants displayed almost undetectable kinase activity, in contrast to the readily observable activity of wild type c-ABL (Figure 2b ). In addition, attempted activation of the D248-274 mutant by introduction of the PP mutations did not rescue any activity (Figures 2a and b, far right lanes) . To test the mutants in the context of BCR-ABL, the deletion mutant constructs were expressed stably in Ba/F3 cells. Unlike p210 BCR-ABL expressing cells, deletion mutants remained dependent on IL-3 for proliferation (Figure 2c) . Although expressed to a similar level in the Ba/F3 cells, the deletion mutants did not show detectable BCR-ABL autophosphorylation (Figure 2d ) and downstream target phosphorylation was absent (see Figure 3b) . In summary, these experiments indicate that the deletion mutant proteins are catalytically inactive. a and b) were created using PyMol. 21 
Coexpression of P-loop deletion mutants does not interfere with the oncogenic activity of native BCR-ABL
In cells coexpressing native and catalytically inactive deletion mutant BCR-ABL heterocomplex formation might decrease oncogenic potential. We, therefore coexpressed wild type and deletion mutant by infecting Ba/F3-p210 cells with D248-274 and D184-274 BCR-ABL retroviruses. To generate sublines with varying mutant to native BCR-ABL ratios, we sorted cells based on low (L), medium (M) and high (H) GFP expression. Coexpressing cell lines were still IL-3 independent (Figure 3a) . Immunoblot of the coexpressing cell lines suggested transphosphorylation of the D248-274 mutant by native BCR-ABL, but not for the D184-274 mutant (Figure 3b) . We propose the reason for this difference may be the lack of the Y185, Y226 and Y232 phosphorylation sites from the D184-274 mutant. 16 As a positive control, p210 was expressed in Ba/F3-p210 cells to show the effect of doubling the BCR-ABL 'dose'. These results were confirmed by coexpressing the deletion mutants with native BCR-ABL in a tetracycline-inducible system. 17 TonB210 cells stably expressing D248-274 and D184-274 became IL-3 independent upon addition of Doxycycline in the cell culture medium to induce p210 BCR-ABL (Supplementary Figure 1a) . Likewise, BCR-ABL autophosphorylation was detected only following p210 induction (Supplementary Figure 1b) . Collectively, these data show that the deletion mutants do not exhibit a dominant-negative effect with respect to BCR-ABL activation and IL-3 independence.
Coexpression of P-loop deletion mutants in Ba/F3-p210 cells increases sensitivity to imatinib
To test whether the deletion mutants may affect imatinib sensitivity, the D248-274 and D184-274 mutant Ba/F3-p210 cell lines were grown in the absence of IL-3 and tested for their sensitivity to imatinib in cell proliferation assays. Unexpectedly, coexpression led to an increase in imatinib sensitivity that was reproducible in multiple experiments (Figures 3c and d) . Furthermore, the increase in imatinib sensitivity was consistently highest in the lines expressing the highest levels of deletion mutant BCR-ABL. Thus, coexpression of deletion mutants consistently results in increased imatinib sensitivity, although the total level of BCR-ABL phosphorylation is increased with their expression. This observation indicates that there is a dominant-negative effect of deletion mutant coexpression with respect to imatinib sensitivity.
Follow-up analysis of patients with detection of a P-loop deletion mutation
To assess possible clinical implications in the eight patients expressing the BCR-ABL deletion mutants the relevant laboratory values were collected and mutation analysis performed on available follow-up samples. In two patients (patients no. 2 and 7) the deletion mutant was detected coincidently with a rise in BCR-ABL transcript levels (Figure 4a) . One of these patients also had the L248V mutation. In four patients, a rise in BCR-ABL occurred 3-21 months after the detection of the deletion (patients no. 1, 4, 5 and 8). Figure 4b shows follow-up cytogenetics and mutation analysis. Of the two patients with the L248V and D248-274 mutations, patient no. 1 relapsed 25 months later; no follow-up data are available for patient no. 3. Of the five patients with the D184-274 mutant, two have also had a kinase domain point mutation found. Another patient with D184-274 obtained a major cytogenetic response (#4) and two maintained a CCR (no. 2 and 8). It is noteworthy that patient no. 4 in whom D184-274 was detected at the original sample had instead detection of D363-444 OOF (exon 7 loss) at the 6-month follow-up sample. In summary, the clinical follow-up in these patients reveals no consistent association between the presence of deletion mutants and relapse.
Discussion
Point mutations in the kinase domain of BCR-ABL are a common and extensively studied mechanism of acquired resistance to imatinib. In contrast, deletion mutations have only recently been described, their incidence is unknown and no functional analysis has been carried out. We detected BCR-ABL deletion mutations in 14 of 101 patients tested by direct sequencing of PCR products. The D248-274 mutant exclusively collocates with the L248V mutation. This is thought to be due to introduction of an alternative splice site by the CTG4GTG substitution at codon 248. 2 However, in our series the most common deletion mutation was D184-274. The lack of detection of this mutation previously is likely to be due to the use of forward sequencing primers localized 3 0 of residue 184, which would detect wild type, but not the D184-274 transcript. The mechanism of exon 4 loss is likely alternative splicing, although it is unclear why this occurs in some patients to a detectable level but not others. Another possibility is that intronic mutations influence splicing in these patients. Unfortunately, this would be difficult to investigate due to the sizes of the ABL introns and the resulting distance of the intron/exon junctions from the breakpoint (4200 Kb). 18 Both P-loop deletion mutants are intrinsically kinase inactive and fail to confer growth factor independence. Therefore, the prediction is that exclusive expression of deletion mutant protein in a CML cell will eliminate BCR-ABL activity and with it the competitive advantage over normal hematopoiesis.
Although, we did not analyze mutant and native BCR-ABL coexpression in single cells, our data are consistent with this assumption. With coexpression, one might predict that a kinase inactive allele may exhibit a dominant-negative effect on the active allele. However, we did not find evidence for this in terms of growth properties and signaling activity. Unexpectedly, coexpression of deletion mutant BCR-ABL reproducibly increased imatinib sensitivity. This represents a dominant-negative effect with respect to the native protein's sensitivity to inhibition. The underlying mechanism of this imatinib sensitization remains elusive. One possibility is that heterodimers may stabilize an inactive BCR-ABL conformation that is able to bind imatinib. 19 In the case of L248V/D248-274, the high intrinsic imatinib resistance of the point mutant may overcome any handicap imposed by the deletion mutant. On the other hand, the tendency of this mutation to favor the generation of D248-274 alleles and the additional effects on imatinib sensitivity may attenuate the biological phenotype of this mutant, which is highly imatinib resistant in vitro.
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The discovery of the D184-274 mutation extends an emerging body of work suggesting that alternative splicing in BCR-ABL is more common than previously thought. A recent report described alternatively spliced BCR-ABL transcripts joining BCR to either ABL exon 4 or 5, which results in out of frame translation of ABL. 4 These events were shown to occur in 80% of newly diagnosed CML cases tested with gel extraction and sequencing of the smaller bands. 4 This high frequency of alternatively spliced products is similar to preliminary work by another group. 3 The lower frequency of detection of these transcripts in our patients may be related to our practice of sequencing the entire PCR product (where small transcripts must compete with wild type to show on the chromatogram) and the fact that our cohort consists of patients on imatinib, rather than newly diagnosed. Thus, the majority of CML patients are likely to express BCR-ABL kinase dead fusions at varying levels along with the wild-type protein. The consequences of coexpressing D184-274 and D248-274 mutants with native BCR-ABL in our work is likely to extrapolate to the other alternatively spliced products as well.
Our data show that deletion mutations of BCR-ABL are relatively frequent in patients on imatinib therapy. Given that automated sequencing is used for mutation detection in most labs, it is likely that many deletion mutations are interpreted as high background sequencing traces and therefore escape diagnosis. Do deletion mutations impact the prognosis of patients on imatinib? At least in our relatively small cohort we were unable to detect a correlation between the presence of deletion mutations and outcome. This may reflect the complex interplay between deletion and point mutations. For example, the kinase inactive D248-274 mutant is triggered by the presence of L248V, which confers a high degree of resistance; at the same time coexpression of the deletion mutant increased imatinib sensitivity. Further, it is unknown whether the propensity of a given CML patient to generate splice variants is prognostically good, bad or neutral. Thus, larger studies will be required to definitively determine the prognostic impact of deletion mutations. Figure 4 Clinical data for patients with a P-loop deletion mutation. (a) Available qRT-PCR data for BCR-ABL in patients with a P-loop deletion mutation was graphed for the period of 24 months before and after the original detection of a mutant. The qRT-PCR data is not graphed for patient no. 3 due to the long time period between samples. (b) Clinical timelines are shown to indicate the cytogenetic and mutation analysis before and after the index sample with deletion mutation detection. All patients were taking imatinib during the entire period shown, unless noted at imatinib (IM) start or switch to dasatinib (das). Owing to a cryptic rearrangement in patient no. 1 not apparent on cytogenetics, FISH percentages are indicated instead.
